Evidence map›Paper›PMID 39902542›Full record

ArticleAnti-cancer agents in medicinal chemistry2025

Design, Synthesis, and Molecular Docking Studies of Indolo[3,2-c]Quinolines as Topoisomerase Inhibitors.

Mohamed Badr, Elshaymaa I Elmongy, Ibrahim El Tantawy El Sayed, Yasmine S Moemen, Ashraf Khalil, Doaa Elkhateeb, Reem Binsuwaidan, Hadeer Ali

Abstract read
PubMed Publisher
In one paragraph

Article in Anti-cancer agents in medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mohamed BadrDepartment of Biochemistry, Faculty of Pharmacy, Menoufia University, Menoufia, Egypt.
Elshaymaa I ElmongyDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University, Ain Helwan, Cairo, P.O. Box 11795, Egypt.ORCID 0000-0003-1160-5040
Ibrahim El Tantawy El SayedChemistry Department, Faculty of Science, Menoufia University, Shebin El-Kom, Egypt.
Yasmine S MoemenClinical Pathology Department, National Liver Institute, Menoufia University, Shebin El-Kom, Egypt.
Ashraf KhalilDepartment of Clinical Biochemistry and Molecular Diagnostics, National Liver Institute, Menuofia University, Shebin Elkom, Egypt.
Doaa ElkhateebChemistry Department, Faculty of Science, Menoufia University, Shebin El-Kom, Egypt.
Reem BinsuwaidanDepartment of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh, 11671, Saudi Arabia.
Hadeer AliChemistry Department, Faculty of Science, Menoufia University, Shebin El-Kom, Egypt.

Funding

Princess Nourah bint Abdulrahman University Researchers Supporting Project PNURSP2025R304
6 · The paper itself

Abstract

backgroundThe tetracyclic indoloquinoline ring system has attracted considerable interest in the recent past due to its broad spectrum of biological activities and its binding to various types of nucleic acids.

objectiveThis study aims to elucidate their interactions with DNA and their effects on topoisomerases (TOPO) I and II.

methodsSeveral compounds derived from 6-amino-11H-indolo[3,2-c]quinoline with diverse groups on the quinoline ring have been successfully synthesized according to a previously established protocol where all the synthesized indolo[3,2-c]quinoline derivatives were evaluated

resultsThe tested compounds were more effective at killing MV4-11 leukemia cells than the standard cancer drug cisplatin, as shown by the fact that their IC

conclusionThe results of this study demonstrate that compounds 5g and 8 can be considered promising candidates for further anti-cancer drug development, which might be related to inhibiting TOPO I and TOPO II activities.

Indexed as

Antineoplastic AgentsDNA Topoisomerases, Type IDNA Topoisomerases, Type IIDrug DesignIndolesMolecular Docking SimulationQuinolinesTopoisomerase II InhibitorsTopoisomerase I InhibitorsTopoisomerase InhibitorsAnimalsCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansAntineoplastic AgentsDNA Topoisomerases, Type IDNA Topoisomerases, Type IIIndolesQuinolinesTopoisomerase II InhibitorsTopoisomerase I InhibitorsTopoisomerase Inhibitorsanticancer agentsapoptosisIndoloquinolinemolecular dockingMV4-11 leukemia cells.topoisomerase inhibitors

Identifiers

PMID39902542

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.